The group has over 20 years of experience in clinical and translational research on Alzheimer’s disease. The main scientific interest is the use of neuroimaging techniques and other biomarkers in persons with or at risk for cognitive impairment. Acquisitions and innovations in fundamental neurosciences, ICT, and technology are uptaken and translated for use into a clinical setting for better pathophysiological understanding, diagnosis, prognosis, disease tracking, drug therapy, and rehabilitation. Specific topics of investigation are: the clinical use of imaging and fluid biomarkers; in vivo neurobiology of Alzheimer’s disease; the clinical use of innovative PET ligands; harmonisation of imaging markers for clinical use; development of innovative image analysis environments based on advanced ICT technology.
Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease.
Medial temporal lobe atrophy and posterior atrophy scales normative values.
Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease.
Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.
Département de psychiatrie